

## PROXY: GENOMMA LAB INFORMS THE AMOUNT TO BE PROPOSED OF REMUNERATION FOR THE BOARD OF DIRECTORS AND THE AUDIT & CORPORATE PRACTICES COMMITTEE MEMBERS

**Mexico City, April 14, 2021 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that the remuneration for attending each session of the Board of Directors and the Audit & Corporate Practices Committee will remain the same as previously approved by the Shareholders last year. The total amount is not expected to exceed US\$ 400,000 (four hundred thousand dollars) in the year.

---

### About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker **“LABB” (Bloomberg: LABB: MM)**.